Venus Remedies
VENUSREMNSE

Venus Remedies

₹1,738.10-27.50 (1.56%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
1,715.30
Today’s high
1,764.50
52 week low
424.00
52 week high
2,044.30
Open price
1,715.30
Previous close
1,765.60
Live volume
19,518
Lower circuit
1,651.20
Upper circuit
1,825.00

Fundamentals

Market Cap
₹2,313Cr
ROE
15.49%
P/E Ratio(TTM)
19.91
EPS(TTM)
86.92
P/B Ratio
3.48
Dividend Yield
0.58%
Industry P/E
37.20
Book Value
496.56
Debt to Equity
0.02
Face Value
10

Financial performance

Quarterly
Yearly
All Financials
JUN '26
Revenue (Cr)
₹181
-31.35%
Profit (Cr)
₹22.97
-51.64%
075150225300
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Revenue growthValue
1Y (TTM)+29%
3Y CAGR+3%
Profit growthValue
1Y (TTM)+139%
3Y CAGR+4%

About

Venus Remedies Limited is a research-driven Indian pharmaceutical company with a global presence, specializing in the injectables space. The company's core vision is to leave a positive footprint on human health by creating an institution that transcends the mortal being. A key part of its Mission 2026 is to foster innovative therapies that target the major health challenge of Antimicrobial Resistance. It develops solutions for human ailments in critical areas like oncology, neurology, pain management, and also has a herbal product portfolio. The company's priority regions are the Middle East, South-East Asia, Africa, and Latin America, where it aims to be a partner of choice. With over 1040 marketing authorisations and more than 25 GMP approvals, the company has expanded its boundaries to over 90 countries.;
CEO/MD
Pawan Chaudhary
Founded in
1989
NSE symbol
VENUSREM

Shareholding pattern

Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Shareholder details

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
PfizerPFIZER
₹4,978.20
+58.20 (1.18%)
L
    H
    22,759.9530.965.42
    ₹2,560.80
    +31.10 (1.23%)
    L
      H
      19,444.5528.685.42
      ₹7,415.50
      -91.50 (1.22%)
      L
        H
        18,526.25109.2221.23
        Natco PharmaNATCOPHARM
        ₹882.40
        +4.90 (0.56%)
        L
          H
          15,806.4513.811.71
          Livesquawk
          Venus Remedies Q1 EBITDA rises to ₹341M from ₹101M YoY. EBITDA margin expands to 19.1% from 7.7% YoY for Venus Remedies.
          2026

          7
          Aug
          Dividend
          Ex date
          ₹10.00
          per share

          For each share you hold, you will receive ₹10.00
          Dividend amount₹10.00 per share
          Dividend TypeFinal
          Ex Date7 Aug ‘26
          Record Date7 Aug ‘26
          Announcement date26 May ‘26
          20
          Jul
          Quarterly Result
          Release date

          26
          May
          Dividend
          Announced
          ₹10.00
          per share

          For each share you hold, you will receive ₹10.00
          Dividend amount₹10.00 per share
          Dividend TypeFinal
          Ex Date7 Aug ‘26
          Record Date7 Aug ‘26
          Announcement date26 May ‘26
          26
          May
          Annual Result
          Release date
          29
          Jan
          Quarterly Result
          Release date
          2025
          10
          Nov
          Quarterly Result
          Release date
          1
          Aug
          Quarterly Result
          Release date
          Events calendar
          View upcoming events in other stocks